@talhabadarmd.bsky.social
Hematologist-Oncologist at Mayo Clinic. Interest in Acute Leukemia and Myeloid disorders.
👇🏽 Trial finding that led to approval:
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽
29.10.2025 21:25 — 👍 0 🔁 1 💬 0 📌 0
AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽
29.10.2025 21:25 — 👍 0 🔁 1 💬 0 📌 0Olutasidenib alone or combined with azacitidine in pts with IDH1m MDS ashpublications.org/bloodadvances/…
👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19)
👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 mo #mds
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML ashpublications.org/bloodadvances/…
#Agile_study:mOS 24 mo.
#cross-trial comparison; VIALE-A trial mOS IDH2-m AML ( 27.5 vs 13 mo) & IDH1-m AML (median 10.2 vs 2.2 mo) #leusm #AML
👇🏽 Trial finding that led to approval:
Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
